Levo Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2016-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.levotx.com
Clinical Trials
1
Active:0
Completed:1
Trial Phases
1 Phases
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 3
1 (100.0%)Phase 3 Study of Intranasal Carbetocin (LV-101) in Patients With Prader-Willi Syndrome
Phase 3
Completed
- Conditions
- Prader-Willi Syndrome
- Interventions
- Drug: placeboDrug: 3.2 mg intranasal carbetocinDrug: 9.6 mg intranasal carbetocin
- First Posted Date
- 2018-08-28
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- Levo Therapeutics, Inc.
- Target Recruit Count
- 130
- Registration Number
- NCT03649477
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Children's Hospital of Los Angeles (USC), Los Angeles, California, United States
News
No news found